Advocates Tez Anderson & Josh Robbins to Host Facebook Live Conversation on HIV/AIDS & Aging Awareness Day to Discuss Issues ...
September 18 2017 - 10:07AM
Business Wire
(NASDAQ: JAGX) – Today marks National HIV/AIDS and Aging
Awareness Day (NHAAD), observed annually to focus on the challenges
facing the aging population with regards to HIV prevention,
testing, care and treatment.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170918005864/en/
Advocates Tez Anderson and Josh Robbins
to host Facebook Live Conversation on 9/18 at 12 p.m. PT about
aging in the HIV+ / AIDS community. (Photo: Business Wire)
Let’s Kick ASS founder Tez Anderson, a long-term AIDS survivor,
and Josh Robbins, an HIV positive patient advocate and GLAAD
Award-nominated blogger for imstilljosh.com, are hosting a Facebook
Live Conversation on Monday, September 18th at 12:00 p.m. PT to
talk about important issues related to aging within the HIV+ / AIDS
community.
This Facebook Live conversation is sponsored by Napo
Pharmaceuticals, a wholly-owned subsidiary of Jaguar Health, Inc.
You can watch live here: http://fb.com/imstilljosh.
During the live broadcast, Tez Anderson and Josh Robbins will
discuss:
- How long term survivors and newly
diagnosed individuals can learn from one another
- While Tez is a long-term survivor of
HIV, Josh was more recently diagnosed (2012). Each brings to bear
different perspectives about their journey living with HIV.
- This live discussion will honestly
examine how the two sets of people living with HIV can offer wisdom
and fresh perspectives to each other.
- Some of the side effects of living with
HIV
- The gastrointestinal (GI) tract -
diarrhea, bloating and abdominal pain
- Skin - seborrheic dermatitis or skin
rashes
- Mental health – depression, anxiety,
mood changes
- Other – lipodystrophy, osteoporosis,
osteopenia, diabetes, high blood pressure
Napo Pharmaceuticals recognizes the importance of HIV/AIDS and
Aging Awareness Day, which it believes will increase significantly
as the HIV+ population gets older. According to data from the U.S.
Centers for Disease Control and Prevention, currently over 50% of
people living with HIV are over age 50; by 2020 it will increase to
70 percent.
About Jaguar Health, Inc.
Jaguar Health, Inc. is a natural-products pharmaceuticals
company focused on developing and commercializing novel,
sustainably derived gastrointestinal products for both human
prescription use and animals on a global basis. Our wholly-owned
subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and
commercializing proprietary human gastrointestinal pharmaceuticals
for the global marketplace from plants used traditionally in
rainforest areas. Our Mytesi® (crofelemer) product is approved by
the U.S. FDA for the symptomatic relief of noninfectious diarrhea
in adults with HIV/AIDS on antiretroviral therapy. Mytesi® is in
development for multiple possible follow-on indications, including
chemotherapy-induced diarrhea; orphan-drug indications for infants
and children with congenital diarrheal disorders and short bowel
syndrome; supportive care for inflammatory bowel disease (IBD);
irritable bowel syndrome (IBS); and as a second-generation
anti-secretory agent for use in cholera patients. Canalevia™ is our
lead animal prescription drug candidate, intended for treatment of
various forms of diarrhea in dogs. Equilevia™ is Jaguar’s
non-prescription product for total gut health in equine athletes.
Canalevia™ and Equilevia™ contain ingredients isolated and purified
from the Croton lechleri tree, which is sustainably harvested.
Neonorm™ Calf and Neonorm™ Foal are Jaguar’s lead non-prescription
animal products. Mytesi®, Canalevia™, Equilevia™ and Neonorm™ are
distinct products that act at the same last step in a physiological
pathway generally present in mammals.
For more information about Jaguar, please visit jaguar.health.
For more information about Napo, visit napopharma.com.
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements.” These include statements regarding
possible follow-on indications for Mytesi®. In some cases, you can
identify forward-looking statements by terms such as “may,” “will,”
“should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “potential” or “continue” or the negative of these terms
or other similar expressions. The forward-looking statements in
this release are only predictions. Jaguar has based these
forward-looking statements largely on its current expectations and
projections about future events. These forward-looking statements
speak only as of the date of this release and are subject to a
number of risks, uncertainties and assumptions, some of which
cannot be predicted or quantified and some of which are beyond
Jaguar’s control. Except as required by applicable law, Jaguar does
not plan to publicly update or revise any forward-looking
statements contained herein, whether as a result of any new
information, future events, changed circumstances or otherwise.
Jaguar-JAGX
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170918005864/en/
KCSA Strategic CommunicationsKate Tumino,
212-896-1252ktumino@kcsa.comLisa Lipson,
508-843-6428llipson@kcsa.com
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Sep 2023 to Sep 2024